ApprovedFDA approval

Zaynich (cefepime and zidebactam)

Wockhardt Bio AG

Marketer take

A new IV beta-lactam combination for cUTI, so hospital ID physicians, pharmacists and stewardship committees decide whether it is reserved for resistant organisms.

Sponsor company
Wockhardt Bio AG
Indication
To treat complicated urinary tract infections, including pyelonephritis, caused by designated susceptible microorganisms
Therapeutic area
Infectious disease
Event
FDA approval
Date
May 29, 2026
Status
Approved
Source
FDA page
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move